BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27797785)

  • 1. Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink.
    Hicks BM; Yin H; Yu OH; Pollak MN; Platt RW; Azoulay L
    BMJ; 2016 Oct; 355():i5340. PubMed ID: 27797785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus.
    Faillie JL; Yu OH; Yin H; Hillaire-Buys D; Barkun A; Azoulay L
    JAMA Intern Med; 2016 Oct; 176(10):1474-1481. PubMed ID: 27478902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incretin-based Drugs and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes.
    Abrahami D; Yin H; Yu OHY; Pollak MN; Azoulay L
    Epidemiology; 2018 Mar; 29(2):246-253. PubMed ID: 29283894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study.
    Abrahami D; Douros A; Yin H; Yu OH; Faillie JL; Montastruc F; Platt RW; Bouganim N; Azoulay L
    BMJ; 2018 Dec; 363():k4880. PubMed ID: 30518618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study.
    Abrahami D; Douros A; Yin H; Yu OHY; Renoux C; Bitton A; Azoulay L
    BMJ; 2018 Mar; 360():k872. PubMed ID: 29563098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink.
    Gamble JM; Chibrikov E; Midodzi WK; Twells LK; Majumdar SR
    BMJ Open; 2018 Oct; 8(10):e023830. PubMed ID: 30297350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study.
    Pradhan R; Lu S; Yin H; Yu OHY; Ernst P; Suissa S; Azoulay L
    BMJ; 2022 Nov; 379():e071380. PubMed ID: 36318979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incretin-Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes.
    Faillie JL; Yin H; Yu OHY; Herrero A; Altwegg R; Renoux C; Azoulay L
    Clin Pharmacol Ther; 2022 Jan; 111(1):272-282. PubMed ID: 34587280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes.
    Brauer R; Wei L; Ma T; Athauda D; Girges C; Vijiaratnam N; Auld G; Whittlesea C; Wong I; Foltynie T
    Brain; 2020 Oct; 143(10):3067-3076. PubMed ID: 33011770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study.
    Azoulay L; Filion KB; Platt RW; Dahl M; Dormuth CR; Clemens KK; Durand M; Juurlink DN; Targownik LE; Turin TC; Paterson JM; Ernst P;
    BMJ; 2016 Feb; 352():i581. PubMed ID: 26888382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weight-lowering Effects of Glucagon-like Peptide-1 Receptor Agonists and Detection of Breast Cancer Among Obese Women with Diabetes.
    Santella C; Yin H; Hicks BM; Yu OHY; Bouganim N; Azoulay L
    Epidemiology; 2020 Jul; 31(4):559-566. PubMed ID: 32282437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-Like Peptide 1 Receptor Agonists and Risk of Anaphylactic Reaction Among Patients With Type 2 Diabetes: A Multisite Population-Based Cohort Study.
    Pradhan R; Patorno E; Tesfaye H; Schneeweiss S; Yin H; Franklin J; Pawar A; Santella C; Yu OHY; Renoux C; Azoulay L
    Am J Epidemiol; 2022 Jul; 191(8):1352-1367. PubMed ID: 35136902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incretin-based drugs and risk of lung cancer among individuals with type 2 diabetes.
    Rouette J; Yin H; Yu OHY; Bouganim N; Platt RW; Azoulay L
    Diabet Med; 2020 May; 37(5):868-875. PubMed ID: 32124472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis.
    Azoulay L; Filion KB; Platt RW; Dahl M; Dormuth CR; Clemens KK; Durand M; Hu N; Juurlink DN; Paterson JM; Targownik LE; Turin TC; Ernst P; ; Suissa S; Dormuth CR; Hemmelgarn BR; Teare GF; Caetano P; Chateau D; Henry DA; Paterson JM; LeLorier J; Levy AR; Ernst P; Platt RW; Sketris IS
    JAMA Intern Med; 2016 Oct; 176(10):1464-1473. PubMed ID: 27479930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon like peptide-1 receptor agonists and the risk of skin cancer among patients with type 2 diabetes: Population-based cohort study.
    Pradhan R; Yu OHY; Platt RW; Azoulay L
    Diabet Med; 2024 Apr; 41(4):e15248. PubMed ID: 37876318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study.
    Ueda P; Wintzell V; Melbye M; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Svanström H; Pasternak B
    Diabetologia; 2021 Oct; 64(10):2204-2214. PubMed ID: 34254177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.
    Dawwas GK; Smith SM; Park H
    Cardiovasc Diabetol; 2018 Jul; 17(1):102. PubMed ID: 30016946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study.
    Faillie JL; Azoulay L; Patenaude V; Hillaire-Buys D; Suissa S
    BMJ; 2014 Apr; 348():g2780. PubMed ID: 24764569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.